Inhibiting IRE1α pathway could be novel therapeutic strategy for lupus
A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
List view / Grid view
A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
Researchers have imaged the entire Survival Motor Neuron complex using X-ray diffraction analysis, among other techniques.
Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
Researchers have developed a new tool that can add or remove sugar from proteins, which could be used to treat currently "undruggable" targets.
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
A new study has revealed that immunoglobulin-M antibodies recognise microvesicles, which are critical for the progression of thrombosis.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.